Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine

Pediatric Infectious Disease Journal

Volumn 15, Issue 11, 1996, Pages 1012-1018

  Dennehy, Penelope H ^a,b   Rodgers Jr , George C ^c   Ward, Richard L ^d   Markwick, Alison J ^e   Mack, Michael ^e   Zito, Edward T ^e  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c University of Louisville School of Medicine   (United States)

^d Gamble Institute of Medical Research   (United States)

^e WYETH AYERST RESEARCH   (United States)

Author keywords

immunogenicity; reactogenicity; Rotavirus vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; FEVER; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN A; INFANT; ROTAVIRUS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 10544227758     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199611000-00016     Document Type: Article

References (22)

1. Ho MS, Glass RI, Pinsky PF, Anderson LJ. Rotavirus as a cause of childhood morbidity and mortality in the United States. J Infect Dis 1988;158:1112-6.
2. Institute of Medicine. Appendix D-13: the prospects for immunizing against rotavirus. In: New vaccine development, establishing priorities: diseases of importance in developing countries. Washington, DC: National Academy Press, 1986: 308-18.
3. Kapikian AZ, Flores J, Hoshino Y, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controlled by a "Jennerian" approach to vaccination. J Infect Dis 1986; 153:815-22.
4. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortment rotavirus as potential live rotavirus vaccine candidates. J Virol 1985;53:949-54.
5. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986;24:822-6.
6. Dagan R, Kassis I, Sarov B, et al. Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus vaccine in neonates. Pediatr Infect Dis J 1992;11:991-6.
7. Perez-Schael I, Blanco M, Vilar M, et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. J Clin Microbiol 1990;28:553-8.
8. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273:1191-6.
9. Rennels MB, Glass RI, Dennehy PH, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines: report of the national multicenter trial. Pediatrics 1996;97: 7-13.
10. Flores J, Perez-Schael I, Gonzalez M, et al. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;1:882-4.
11. Lanata CF, Midthun K, Black RE, et al. Safety, immunogenicity and protective efficacy of one and three doses of rhesus tetravalent rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996;174:268-75.
12. Linhares AC, Gabbay YB, de Freitas RB, et al. Immunogenicity, safety and efficacy of rhesus-human, reassortant rotavirus (RRV-tetravalent) vaccine in Belém, Brazil. In: Abstracts of the Fifth Rotavirus Vaccine Workshop: current issues and future developments. Atlanta, GA: Centers for Disease Control and Prevention, 1995.
13. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989;159:753-7.
14. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986;153: 832-9.
15. Ward RL, Bernstein DI, Shukla R, et al. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989;159:79-88.
16. Knowlton D, Spector D, Ward R. Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods 1991;33:127-34.
17. Ward RL, McNeal MM, Sander DS, Greenberg HB, Bernstein DI. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol 1993;67:464-8.
18. Chiba S, Nakata S, Ukae S, Adachi N. Virological and serological aspects of immune resistance to rotavirus gastroenteritis. Clin Infect Dis 1993;16:S117-21.
19. Flores J, Perez-Schael I, Blanco M, et al. Reactions to and antigenicity of two human-rhesus rotavirus reassortant vaccine candidates of serotypes 1 and 2 in Venezuelan infants. J Clin Microbiol 1989;27:512-8.
20. Green KY, Taniguchi K, Mackow ER, Kapikian AZ. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 1990;161:667-79.
21. Ward RL, Clemens JD, Knowlton DR, et al. Evidence that protection against rotavirus diarrhea after natural infection is not dependent on serotype-specific neutralizing antibody. J Infect Dis 1992;166:1251-7.
22. Flores J, Perez-Schael I, Blanco M, et al. Reactogenicity and immunogenicity of a high-titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 1993;31: 2439-45.